| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1397883 | European Journal of Medicinal Chemistry | 2009 | 7 Pages |
In the search of new therapeutic tools for the treatment of American Trypanosomiasis, the largest parasitic disease burden in the American continent, three series of novel ruthenium complexes of the formula [RuCl2(HL)2], [RuCl3(dmso)(HL)] and [RuCl(PPh3)(L)2] with bioactive 5-nitrofuryl containing thiosemicarbazones as ligands (HL neutral, L monoanionic) were synthesized and characterized. Their in vitro growth inhibition activity against Trypanosoma cruzi and the effect of co-ligands in related physicochemical properties i.e. nitro moiety redox potential, lipophilicity and free radical scavenger capacity were evaluated. Results show that although a loss of activity was observed as a consequence of ruthenium complexation, lipophilicity and free radical scavenger capacity of the obtained complexes could be correlated to their trypanocidal effect.
Graphical abstractRuthenium complexes of the formula [RuIICl2(HL)2], [RuIIICl3(dmso)(HL)] and [RuIIICl(PPh3)(L)2] with bioactive ligands against Chagas disease were obtained. The effect of co-ligands on the biological activity and related physicochemical properties resulted evident.Figure optionsDownload full-size imageDownload as PowerPoint slide
